Article
The PI3 kinase signaling pathway in prostate cancer.
Current cancer drug targets - 1 Feb 2013
Elfiky Aymen A, Jiang Zhenyang
Abstract excerpt
Despite recent advances in our understanding of the biological basis of prostate cancer, the management of the disease, especially in the castration-resistant phase, remains a significant challenge. Deregulation of the phosphatidylinositol 3-kinase (PI3K) pathway is increasingly implicated in a number of malignancies, including prostate carcinogenesis. In this review, we detail the role of this pathway in the...
Topics
Join the communities discussing this publication.